Company intelligence / Profile preview

Erimos Pharmaceuticals

Houston, Texas, United Stateserimos.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Erimos Pharmaceuticals focuses on developing small molecule drugs for cancer and viral diseases. Its lead compound, terameprocol, has completed multiple Phase I trials in various cancers and entered a Phase I/II trial for high-grade glioma. Preclinical studies suggest anti-tumor and anti-virus activity. Some pipeline programs have been discontinued or are pending further development.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

terameprocol

Partnerships

Collaborations with research institutions such as the Adult Brain Tumor Consortiuminvestor relationship with Johns Hopkins Technology Ventures.

Beyond the preview

Go deeper on Erimos Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erimos Pharmaceuticals.

Explore the full profile